Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability ...

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened today at $7.10. Effectively assess a stock's risks and ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $7.87, with InvestingPro data showing the stock is currently trading below its Fair... In a recent ...

Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for upcoming earnings announcements.

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said ...